Presentation is loading. Please wait.

Presentation is loading. Please wait.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Published byEncarnación Ayala Rivero Modified over 6 years ago

Similar presentations

Presentation on theme: "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled."— Presentation transcript:

1 Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)  Kim Papp, MD, PhD, Kristian Reich, MD, PhD, Craig L. Leonardi, MD, Leon Kircik, MD, Sergio Chimenti, MD, Richard G.B. Langley, MD, ChiaChi Hu, EdM, MS, Randall M. Stevens, MD, Robert M. Day, PhD, Kenneth B. Gordon, MD, Neil J. Korman, MD, PhD, Christopher E.M. Griffiths, MD, FMedSci  Journal of the American Academy of Dermatology  Volume 73, Issue 1, Pages (July 2015) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis 1 study design. ∗Doses of apremilast were titrated during the first week of administration and at week 16 when placebo patients were switched to apremilast. §Patients restarted apremilast at the time of loss of effect versus baseline (loss of 75% or greater reduction from baseline Psoriasis Area and Severity Index score [PASI-75]) but no later than week 52. ‡Patients initially on placebo or randomized to apremilast 30 mg twice a day (BID) who did not attain a PASI-75 were able to add topicals and/or ultraviolet (UV) B phototherapy at week 32 at the discretion of the investigator. Journal of the American Academy of Dermatology  , 37-49DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Patient disposition. ∗One death occurred in a patient randomized to apremilast after receiving the last dose of study medication in the placebo-controlled phase. The patient was considered to have completed the placebo-controlled phase. §Includes 4 patients who had a 75% or greater reduction from baseline Psoriasis Area and Severity Index score, were erroneously not rerandomized, and completed the study. BID, Twice a day. Journal of the American Academy of Dermatology  , 37-49DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 A, Mean percentage change in Nail Psoriasis Severity Index (NAPSI) score. Reduction in NAPSI score indicates improvement. Patients with a non-zero baseline value and 1 or more postbaseline values are included. B, Proportion of patients achieving Scalp Physician Global Assessment (ScPGA) score 0 (clear) or 1 (minimal) at week 16. Patients with ScPGA score of 3 or more (moderate to very severe) at baseline and 1 or more postbaseline values are included. BID, Twice a day. ∗P < versus placebo. Journal of the American Academy of Dermatology  , 37-49DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 A, Proportion of patients achieving 75% or greater reduction from baseline Psoriasis Area and Severity Index (PASI) score (PASI-75) response over 32 weeks. B, Mean percentage improvement in PASI from baseline over 32 weeks. C, Mean change (mm) in pruritus visual analog scale (VAS) score from baseline over 32 weeks. Two-sided 95% confidence intervals are shown. BID, Twice a day. Journal of the American Academy of Dermatology  , 37-49DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Mean percentage change (2-sided 95% confidence intervals) in Psoriasis Area and Severity Index (PASI) over 52 weeks. A, Patients randomized to apremilast at baseline with 75% or greater reduction from baseline PASI score (PASI-75) response at week 32 who were rerandomized to apremilast (data for patients who were rerandomized to placebo during the randomized treatment withdrawal phase are not shown). B, Patients randomized to placebo at baseline who were PASI-75 responders at week 32 and entered the randomized treatment withdrawal phase. Patient numbers begin at week 2. BID, Twice a day. Journal of the American Academy of Dermatology  , 37-49DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Volume 10, Issue 7, Pages (July 2018)

Volume 10, Issue 7, Pages (July 2018)
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Similar presentations

Ads by Google